Descripción de la empresa
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical entity based in the United States, focusing on developing and selling specific product candidates for medical applications. The company is situated within the healthcare sector and specifically functions in the biotechnology industry, an environment characterized by high research and development costs and significant regulatory scrutiny. FENC currently maintains a market capitalization of $223.74M and employs a workforce of 35 individuals to support its operations. Its annual revenue for the trailing twelve months stands at $44.64M, indicating that the firm has achieved commercial traction despite its relatively small employee base. The market cap figure of $223.74M suggests that investors value the company's pipeline and commercial potential at approximately five times its current annual sales, while the revenue figure reflects a mature commercial stage where the focus has shifted from pure discovery to market expansion.
Salud financiera
The company reported a revenue of $44.64M for the trailing twelve months, yet it recorded a net income of $-9,741,000, revealing a significant gap between top-line generation and profitability due to substantial operational expenses. The EBITDA for the period was $-6,179,333, which aligns closely with the net loss, suggesting that interest and tax expenses are not the primary drivers of the overall negative earnings. Free cash flow stands at $-7,332,250, indicating that the company is burning cash to fund its commercialization efforts and operational requirements. The gross margin is an impressive 91.6%, demonstrating high efficiency in the cost of goods sold relative to sales, while the operating margin is -18.5% and the profit margin is -21.8%, highlighting that overhead and selling, general, and administrative costs are absorbing a large portion of the revenue. The company holds $36.79M in cash and has no reported debt, creating a conservative balance sheet structure that provides ample liquidity to sustain operations without leverage. The current ratio is 6.37, a metric that indicates a very strong ability to cover short-term liabilities with short-term assets, reflecting excellent short-term financial health. Return on equity is -65.8% and return on assets is -6.8%, metrics that reveal that management is currently generating negative returns on the capital employed to run the business.
Evaluación de valoración
The trailing twelve-month P/E ratio is N/A due to the lack of profitability, whereas the forward P/E is 7.17, implying that the market expects earnings to turn positive in the future. The price-to-book ratio is 6.25, suggesting that the market values the company at more than six times its net asset value, which often occurs in biotechnology firms where intangible assets and intellectual property are not fully captured on the balance sheet. The price-to-sales ratio is 5.01, and the EV/EBITDA is -30.25; these alternative metrics indicate that the valuation is heavily reliant on sales growth and revenue multiple rather than traditional earnings-based multiples. The stock has traded between a 52-week low of $4.68 and a 52-week high of $9.92, and without the current price explicitly listed in the source data, the valuation context relies on the proximity to these historical extremes. The beta is 0.93, which indicates that the stock's price volatility is roughly in line with the broader market, moving with a slight dampening effect compared to the overall index.
Growth & Income
Revenue growth year-over-year is 73.8%, demonstrating a robust expansion in sales, while earnings growth is N/A because the company has not yet achieved consistent profitability. The disparity between the high revenue growth and the negative earnings growth indicates that the company is reinvesting a large portion of its top-line gains into operations rather than realizing immediate bottom-line benefits. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that all generated cash flow is retained within the business to fund further growth initiatives. The overall growth and income profile is defined by aggressive top-line expansion coupled with a complete absence of dividend distributions, positioning the firm as a pure growth play dependent on future profitability to attract income-oriented capital.